Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972278 · ClinicalTrials.gov registry record · Phase 1
Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
A Phase 1 study of Lipid Metabolism, sponsored by NewAmsterdam Pharma.
- Active
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT05972278: Active Phase 1 study of Lipid Metabolism, sponsored by NewAmsterdam Pharma.
NCT05972278 is a Phase 1 study of Lipid Metabolism that is active but no longer recruiting, run by NewAmsterdam Pharma. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972278, a Phase 1 study of Lipid Metabolism, is active but no longer recruiting, sponsored by NewAmsterdam Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Primary Outcome
The mean differences (obicetrapib - placebo) in the LDL apoB100 FCR using the baseline measure (no study treatment) compared to the LDL apoB100 FCR of each variable following the Treatment Period.
Conditions Studied
Interventions
- DRUG Obicetrapib
Study Locations (1)
Pennsylvania
- Archna Bajaj, MD - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2023-12-01 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 1 |
What the registry record for NCT05972278 still lists
NCT05972278 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Lipid Metabolism appearing as the primary indexed condition, and to 1 intervention - of which Obicetrapib is the first listed.
NCT05972278 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05972278 about?
NCT05972278 is a clinical study titled "Investigating the Effect of Obicetrapib on Lipoprotein Metabolism". To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
What is the current status of trial NCT05972278?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2023-12-01. Estimated completion is 2024-10-14.
What conditions does trial NCT05972278 study?
This clinical trial studies the following conditions: Lipid Metabolism.
What interventions are being tested in trial NCT05972278?
The interventions under investigation include: Obicetrapib (DRUG).
Who is sponsoring clinical trial NCT05972278?
This trial is sponsored by NewAmsterdam Pharma, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972278 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lipid Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05972278's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI